DGIdb - OXALIPLATIN Drug Record

OXALIPLATIN chembl:CHEMBL414804 ApprovedAntineoplasticImmunotherapy

Alternate Names:

L-OHP
MBP-426 (LIPOSOMAL OXALIPLATIN)
RP-54780
ELOXATIN
OXALIPLATIN
JM-83
NSC-266046
SR-96669
OXALATOPLATINUM
OXALATOPLATIN
DIAMINOCYCLOHEXANE OXALATOPLATINUM
drugbank:00526
rxcui:32592
chemidplus:61825-94-3
pubchem.compound:11947679
chembl:CHEMBL414804

Drug Info:

(3 More Sources)

Publications:

Aguilera et al., 2015, Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer., Oncotarget
Liu et al., 2013, Targeting SRC and tubulin in mucinous ovarian carcinoma., Clin. Cancer Res.
Golan T et al., 2014, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers., Br J Cancer
Samimi et al., 2004, Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells., Clin. Cancer Res.
Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
Yousef AM et al., 2018, The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer., Cancer Chemother Pharmacol
Nahid NA et al., 2018, DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer., Cancer Chemother Pharmacol
Roberto M et al., 2017, Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine., Eur J Clin Pharmacol
Romiti A et al., 2016, The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer., Anticancer Drugs
Cecchin E et al., 2015, MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin., Pharmacogenomics J
Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther
van Huis-Tanja LH et al., 2013, MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer., Pharmacogenet Genomics
Kristensen MH et al., 2010, Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients., J Int Med Res
Boige V et al., 2010, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05., J Clin Oncol
Sharma R et al., 2008, Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients., Clin Cancer Res
Capitain O et al., 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer., Pharmacogenomics J
Marcuello et al., 2006, Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?, Cancer Chemother. Pharmacol.
Stoehlmacher et al., 2002, Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer., J. Natl. Cancer Inst.
Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
Lamas MJ et al., 2011, Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer., Pharmacogenomics
McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
Kim HS et al., 2009, Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study., Gynecol Oncol
Stoehlmacher J et al., 2004, A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer., Br J Cancer
Wild CP et al., 2000, Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia., Int J Cancer
Watson MA et al., 1998, Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution., Carcinogenesis
Booton R et al., 2006, Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer., J Thorac Oncol
Ruzzo A et al., 2007, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy., J Clin Oncol
Lecomte T et al., 2006, Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy., Clin Cancer Res
Georgiadis P et al., 2004, Impact of phase I or phase II enzyme polymorphisms on lymphocyte DNA adducts in subjects exposed to urban air pollution and environmental tobacco smoke., Toxicol Lett
Dandara C et al., 2002, Genetic polymorphism of cytochrome P450 1A1 (Cyp1A1) and glutathione transferases (M1, T1 and P1) among Africans., Clin Chem Lab Med
Garte S et al., 2001, Metabolic gene polymorphism frequencies in control populations., Cancer Epidemiol Biomarkers Prev
Gsur A et al., 2001, Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk., Int J Cancer
Nehmé et al., 1999, Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells., Br. J. Cancer
Arango et al., 2004, Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells., Br. J. Cancer
Hayward et al., 2004, Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect., Mol. Cancer Ther.
Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
Lin et al., 2012, KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells., PLoS ONE
Leone et al., 2016, Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)., Cancer
Peeters et al., 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer., Clin. Cancer Res.
Raats et al., 2011, Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737., Cell Oncol (Dordr)
Douillard et al., 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study., J. Clin. Oncol.
Hariani GD et al., 2014, Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics., BMC Res Notes
Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
Zhao J et al., 2014, Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer., Med Oncol
Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
Scartozzi M et al., 2013, Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients., Pharmacogenomics
Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
Herath et al., 2016, The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis., Mol. Cancer Ther.
Souglakos J et al., 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer., Br J Cancer
Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med
Sclafani et al., 2014, TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial., J. Natl. Cancer Inst.
Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
Pérez-Ramírez C et al., 2016, Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients., Pharmacol Res
Sullivan I et al., 2014, Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy., Cancer Lett
Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
Yan L et al., 2012, Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy., Pharmacogenomics
Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics
Zucali PA et al., 2011, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin., Clin Cancer Res
Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
Kalikaki A et al., 2009, DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer., Clin Lung Cancer
Tibaldi C et al., 2008, Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
Caronia et al., 2009, Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients., Pharmacogenomics J.
Bellone et al., Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy., Anticancer Res.
Fernandez-Rozadilla C et al., 2013, Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration., Pharmacogenomics J
Kim JG et al., 2009, Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin., Cancer Chemother Pharmacol
Ballestrero et al., 2004, Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells., Clin. Cancer Res.
Pander J et al., 2015, Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer., PLoS One
Samimi et al., 2004, Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B., Mol. Pharmacol.
Ding et al., 2014, Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells., Anticancer Drugs
Hamad et al., 2017, Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer., J Natl Compr Canc Netw
Leichman et al., 2006, Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival., J Chemother
Etienne-Grimaldi MC et al., 2010, Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients., Br J Clin Pharmacol
Huang MY et al., 2008, ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study., BMC Cancer
Chen Y et al., 2020, FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer., Onco Targets Ther
Guo C et al., 2017, ZEB1 Promotes Oxaliplatin Resistance through the Induction of Epithelial - Mesenchymal Transition in Colon Cancer Cells., J Cancer

OXALIPLATIN FOXC2

Interaction Score: 3.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
32110058

Sources:
CIViC
OXALIPLATIN MT1A

Interaction Score: 3.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24924344

Sources:
PharmGKB
OXALIPLATIN GNA13

Interaction Score: 3.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
OXALIPLATIN KLC3

Interaction Score: 2.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 22188361 22026922 21449681 19434073

Sources:
PharmGKB
OXALIPLATIN PARD3B

Interaction Score: 1.67

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22310351

Sources:
PharmGKB
OXALIPLATIN CSMD1

Interaction Score: 1.67

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
OXALIPLATIN ERCC2

Interaction Score: 1.5

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 22188361 22026922 21449681 20385995 20078613 19434073 18267032

Sources:
PharmGKB
OXALIPLATIN ERCC1

Interaction Score: 1.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 27498158 25069034 23314736 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB
OXALIPLATIN ZEB1

Interaction Score: 1.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29151941

Sources:
CIViC
OXALIPLATIN MTHFR

Interaction Score: 0.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29845393 29134491 27864592 27557140 25331073 24980946 23407049 20819423 20385995 18245544 17700593 16187112

Sources:
NCI PharmGKB
OXALIPLATIN MGAT4A

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26222057

Sources:
PharmGKB
OXALIPLATIN ATP7B

Interaction Score: 0.67

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15213293

Sources:
NCI
OXALIPLATIN GSTP1

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12072547 27995989 22188361 21449681 20530282 19203783 15213713 10728587 9498276 17409936 17401013 16707601 15093273 12435115 11751440 11307147

Sources:
NCI PharmGKB
OXALIPLATIN ATP7A

Interaction Score: 0.56

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15269138

Sources:
NCI
OXALIPLATIN DKK1

Interaction Score: 0.56

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25788273

Sources:
CIViC
OXALIPLATIN ABCC5

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24924344

Sources:
PharmGKB
OXALIPLATIN SELE

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24980946

Sources:
PharmGKB
OXALIPLATIN DPYD

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17127229

Sources:
NCI
OXALIPLATIN CXCL10

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16101140

Sources:
NCI
OXALIPLATIN PON1

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OXALIPLATIN NOS3

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25545243 19671875

Sources:
PharmGKB
OXALIPLATIN VEGFA

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 24090479 20125120

Sources:
PharmGKB
OXALIPLATIN NQO1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24924344

Sources:
PharmGKB
OXALIPLATIN BCL2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977850

Sources:
ClearityFoundationBiomarkers NCI
OXALIPLATIN BAX

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15545975 14985457

Sources:
NCI
OXALIPLATIN KRAS

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Oxaliplatin + ABT-737

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
23209813 26540314 26341920 21468686 20921465

Sources:
JAX-CKB CIViC
OXALIPLATIN BRAF

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
26637369 19603024 19571295

Sources:
JAX-CKB CIViC
OXALIPLATIN ABCG2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24338217 20530282

Sources:
PharmGKB
OXALIPLATIN PIN1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OXALIPLATIN ABCC2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23314736

Sources:
PharmGKB
OXALIPLATIN BRCA1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25072261

Sources:
ClearityFoundationBiomarkers CIViC
OXALIPLATIN ABL1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10098743

Sources:
NCI
OXALIPLATIN ERBB2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

Indication/Tumor Type gastric adenocarcinoma

Response Type resistant

PMIDs:
24300914 28784859 26432108

Sources:
JAX-CKB
OXALIPLATIN PTGS2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19219602

Sources:
PharmGKB
OXALIPLATIN PTEN

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy KX2-391 + Oxaliplatin

Indication/Tumor Type ovarian mucinous neoplasm

Response Type sensitive

PMIDs:
24100628

Sources:
JAX-CKB
OXALIPLATIN MET

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab

Indication/Tumor Type gastric adenocarcinoma

Response Type resistant

PMIDs:
26432108

Sources:
JAX-CKB
OXALIPLATIN TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Oxaliplatin + ABT-737

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
24957073 21468686

Sources:
JAX-CKB CIViC

NCI: OXALIPLATIN

Version: 14-September-2017

Alternate Names:

C1181 NCI drug code

Drug Info:

Publications:

Stoehlmacher et al., 2002, Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer., J. Natl. Cancer Inst.

Ballestrero et al., 2004, Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells., Clin. Cancer Res.

Bellone et al., Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy., Anticancer Res.

JAX-CKB: Oxaliplatin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Hamad et al., 2017, Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer., J Natl Compr Canc Netw

Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov

Ding et al., 2014, Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells., Anticancer Drugs

PharmGKB: oxaliplatin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res

Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One

Hariani GD et al., 2014, Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics., BMC Res Notes

CIViC: OXALIPLATIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med

Souglakos J et al., 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer., Br J Cancer

Golan T et al., 2014, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers., Br J Cancer

TTD: Oxaliplatin
- Version: 2020.06.01
Alternate Names:

D0Y3ME TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL414804
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: OXALIPLATIN
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:

combination therapy	Oxaliplatin + ABT-737
Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

combination therapy	Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
Indication/Tumor Type	gastric adenocarcinoma
Response Type	resistant

combination therapy	KX2-391 + Oxaliplatin
Indication/Tumor Type	ovarian mucinous neoplasm
Response Type	sensitive

combination therapy	Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab
Indication/Tumor Type	gastric adenocarcinoma
Response Type	resistant

OXALIPLATIN Drug Record

OXALIPLATIN chembl:CHEMBL414804 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 32110058

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24924344

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 22188361 22026922 21449681 19434073

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22310351

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 22188361 22026922 21449681 20385995 20078613 19434073 18267032

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 27498158 25069034 23314736 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29151941

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29845393 29134491 27864592 27557140 25331073 24980946 23407049 20819423 20385995 18245544 17700593 16187112

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26222057

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15213293

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12072547 27995989 22188361 21449681 20530282 19203783 15213713 10728587 9498276 17409936 17401013 16707601 15093273 12435115 11751440 11307147

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15269138

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25788273

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24924344

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24980946

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17127229

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16101140

Interaction Types & Directionality:

n/a

PMIDs:
32110058

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24924344

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29662106 22188361 22026922 21449681 19434073

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22310351

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29662106 22188361 22026922 21449681 20385995 20078613 19434073 18267032

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29662106 27498158 25069034 23314736 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29151941

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
29845393 29134491 27864592 27557140 25331073 24980946 23407049 20819423 20385995 18245544 17700593 16187112

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26222057

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15213293

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12072547 27995989 22188361 21449681 20530282 19203783 15213713 10728587 9498276 17409936 17401013 16707601 15093273 12435115 11751440 11307147

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15269138

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25788273

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24924344

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24980946

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17127229

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16101140

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25545243 19671875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25955730 24090479 20125120

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24924344

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
14977850

Sources:
ClearityFoundationBiomarkers NCI

Interaction Types & Directionality:

n/a

PMIDs:
15545975 14985457

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Oxaliplatin + ABT-737

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
23209813 26540314 26341920 21468686 20921465

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a